Currently, there are 80.10M common shares owned by the public and among those 78.05M shares have been available to trade.
The company’s stock has a 5-day price change of -1.82% and -45.94% over the past three months. CTMX shares are trading -35.45% year to date (YTD), with the 12-month market performance down to -75.56% lower. It has a 12-month low price of $0.60 and touched a high of $5.85 over the same period. CTMX has an average intraday trading volume of 894.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.34%, -22.35%, and -42.21% respectively.
Institutional ownership of CytomX Therapeutics Inc (NASDAQ: CTMX) shares accounts for 58.41% of the company’s 80.10M shares outstanding.
It has a market capitalization of $53.26M and a beta (3y monthly) value of 1.36. The stock’s trailing 12-month PE ratio is 1.69, while the earnings-per-share (ttm) stands at $0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.38% over the week and 7.84% over the month.
Earnings per share for the fiscal year are expected to decrease by -108.95%, and -1767.65% over the next financial year.
Looking at the support for the CTMX, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on May 28, 2024, with the firm’s price target at $2.25-$3.50. Wedbush coverage for the CytomX Therapeutics Inc (CTMX) stock in a research note released on May 09, 2024 offered a Outperform rating with a price target of $8. BMO Capital Markets on their part issued Market Perform rating on November 14, 2022.
